Correction: Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand (Vaccines, (2023), 11, 4, (749), 10.3390/vaccines11040749)

Abstract

The authors wish to make the following corrections to this published paper [1]. In Figure 1, the names of the vaccines have been replaced with their common names, i.e., Comirnaty has been replaced with BNT162B2, AstraZeneca has been replaced with ChA-dOx1-nCoV, Moderna has been replaced with MRNA-1273 and Sinopharm has been replaced with BBIBP-CorV. The corrected Figure 1 is shown below: In Table 1, we have changed the unit of the number of vaccination doses administered from per 1 million doses to per 100,000 vaccination doses administered and corrected the errors for the overall AEFI rate from 1.95 to be 0.195 per 100,000 doses. We have corrected the number of reported ages for ChAdOx1-nCoV and BNT162b from 21 and 166 to 20 and 165, respectively. The corrected Table 1 is shown below: In Table 2, we have added a remark about the incidence of myocarditis in ChAdOx1-nCoV under Table 2 and changed the incidence of myocarditis in ChAdOx1-nCoV in children aged 12 to 17 to “NA”. The reason we decided to modify this is to avoid confusion, since ChAdOx1-nCoV was not recommended for people under 18 years old in Thailand, but there were some errors that occurred during the campaign as reported. Therefore, we think it would be clearer for readers if we remove the rate of ChAdOx1-nCoV among vaccinees age 12–17 from the table to the footnote. The corrected Table 2 is shown below: The authors apologize for any inconvenience this may have caused and affirm that the scientific conclusions remain unaffected. The original publication has also been updated.